Oestrogen receptor: a stable phenotype in breast cancer
- PMID: 8554983
- PMCID: PMC2074280
- DOI: 10.1038/bjc.1996.2
Oestrogen receptor: a stable phenotype in breast cancer
Abstract
Oestrogen receptor (ER) expression in breast cancer is regarded as a phenotype that may change during the natural history of the disease or during endocrine therapy. It has been suggested that in up to 70% of tumours that show acquired resistance the mechanism may be changed in ER status from positive to negative. This paper proposes an alternative hypothesis that ER expression in a stable phenotype in breast cancer. The paper reviews the literature on ER expression during the natural history of breast cancer in patients and also presents data on the effect of endocrine therapy on ER expression. If the alternative hypothesis is true it has important implications for treatment from chemoprevention to acquired endocrine resistance in advanced disease. Equally, if the hypothesis is true, attempts to develop laboratory models of endocrine resistance where ER-positive tumours become ER negative need to be re-evaluated.
Similar articles
-
bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer.Br J Cancer. 1994 Jan;69(1):135-9. doi: 10.1038/bjc.1994.22. Br J Cancer. 1994. PMID: 8286195 Free PMC article.
-
Irreversible loss of the oestrogen receptor in T47D breast cancer cells following prolonged oestrogen deprivation.Br J Cancer. 1996 Oct;74(8):1227-36. doi: 10.1038/bjc.1996.521. Br J Cancer. 1996. PMID: 8883409 Free PMC article.
-
High incidence of oestrogen receptor negative progesterone receptor positive phenotype in Indian breast cancer: fact or fiction?Indian J Pathol Microbiol. 2005 Apr;48(2):199-201. Indian J Pathol Microbiol. 2005. PMID: 16758664
-
Why are estrogen-receptor-negative breast cancers more aggressive than the estrogen-receptor-positive breast cancers?Invasion Metastasis. 1994-1995;14(1-6):329-36. Invasion Metastasis. 1994. PMID: 7657526 Review.
-
Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk.Endocr Relat Cancer. 2006 Dec;13 Suppl 1:S15-24. doi: 10.1677/erc.1.01273. Endocr Relat Cancer. 2006. PMID: 17259554 Review.
Cited by
-
Statin-induced anti-proliferative effects via cyclin D1 and p27 in a window-of-opportunity breast cancer trial.J Transl Med. 2015 Apr 29;13:133. doi: 10.1186/s12967-015-0486-0. J Transl Med. 2015. PMID: 25925673 Free PMC article. Clinical Trial.
-
Breast cancer oestrogen independence mediated by BCAR1 or BCAR3 genes is transmitted through mechanisms distinct from the oestrogen receptor signalling pathway or the epidermal growth factor receptor signalling pathway.Breast Cancer Res. 2005;7(1):R82-92. doi: 10.1186/bcr954. Epub 2004 Nov 16. Breast Cancer Res. 2005. PMID: 15642172 Free PMC article.
-
The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer.J Clin Invest. 2007 Jan;117(1):218-28. doi: 10.1172/JCI28803. Epub 2006 Dec 7. J Clin Invest. 2007. PMID: 17160137 Free PMC article.
-
Insights into how phosphorylation of estrogen receptor at serine 305 modulates tamoxifen activity in breast cancer.Mol Cell Endocrinol. 2019 Mar 1;483:97-101. doi: 10.1016/j.mce.2019.01.014. Epub 2019 Jan 16. Mol Cell Endocrinol. 2019. PMID: 30659843 Free PMC article. Review.
-
Genetic screening reveals an essential role of p27kip1 in restriction of breast cancer progression.Cancer Res. 2007 Sep 1;67(17):8032-42. doi: 10.1158/0008-5472.CAN-07-0083. Cancer Res. 2007. PMID: 17804714 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical